Trevi Therapeutics Inc
NASDAQ:TRVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Trevi Therapeutics Inc
NASDAQ:TRVI
|
US |
|
N
|
Noram Lithium Corp
F:N7R
|
CA |
|
A
|
Air China Ltd
SWB:AD2
|
CN |
|
Alfio Bardolla Training Group SpA
MIL:ABTG
|
IT |
|
T
|
Triad Group PLC
SWB:TD8
|
UK |
|
G
|
Glen Eagle Resources Inc
XTSX:GER
|
CA |
Intrinsic Value
Is TRVI undervalued or overvalued?
See the intrinsic value estimate for Trevi Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
TRVI looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with TRVI’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Trevi Therapeutics Does
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio, an oral medicine based on nalbuphine, for people with serious chronic itching and chronic cough linked to certain diseases. It is not a broad drug maker with many products; its business is centered on moving this one drug candidate through testing and, if approved, turning it into a prescription therapy for patients and the doctors who treat them.
- Headquarters
- United States of America US
- Employees
- 34
- IPO date
- May 7, 2019
Revenue & Expenses Breakdown
Trevi Therapeutics Inc
Earnings Waterfall
Trevi Therapeutics Inc
The intrinsic value for Trevi Therapeutics Inc (TRVI) under the Base Case is hidden USD.
Compared with the current market price of 12.49 USD, the stock appears hidden.